Facilitated By

San Antonio Medical Foundation

A PHASE 3, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF PAMREVLUMAB IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Nambiar, Anoop
Funded by
FIBROGEN, INC.
Research Start Date
Status
Active
Collaborative Project
Clinical Care
Drug Discovery
Other